• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by Churchill Capital Corp XI

    7/9/26 4:30:13 PM ET
    $CCXI
    Get the next $CCXI alert in real time by email
    425 1 ea0297553-425_churchill11.htm FORM 425

    Filed by Churchill Capital Corp XI pursuant to Rule 425

    under the Securities Act of 1933, as amended,

    and deemed filed pursuant to Rule 14a-12

    under the Securities Exchange Act of 1934, as amended

    Subject Company: Churchill Capital Corp XI (File No. 001-43020)

     

    Set forth below is a transcript of Peggy Johnson’s interview with Fox Business, in which the proposed business combination between Churchill Capital Corp XI (“Churchill”) and Agility Robotics, Inc. (“Agility”) is discussed.

     

    Mornings with Maria ● July 9, 2026

    Speakers: Maria Bartiromo (Fox Business anchor) and Peggy Johnson (CEO, Agility Robotics)

     

    MARIA BARTIROMO: The humanoid robot race is heating up. One of the industry’s biggest players is headed to Wall Street. Agility Robotics, the company behind humanoid robot Digit, is preparing to go public through a SPAC with Churchill Capital Corp XI, valuing the company at about $2.5 billion. Now, the robot Digit already operates with customers in real-world environments, including Amazon, GXO, Toyota Canada and Germany’s Schaeffler. Joining me now is Agility Robotics CEO Peggy Johnson. Peggy, good morning. Congratulations on the upcoming IPO and taking the company public. You’ll be raising new money, what are the plans for that money? Why go public now?

     

    PEGGY JOHNSON: Well, we have over $300 million in booked orders right now, and we’d like to accelerate that. We have a large and growing pipeline of customers who need robots. They need a solution to their labor shortages.

     

    MARIA: So, tell me about the robots and where they’re filling roles in this labor shortage.

     

    PEGGY JOHNSON: The robots are humanoid, and they step into dirty, very repetitive and sometimes dangerous jobs that are very hard to fill. These are tasks like lifting things over and over again, which can be very injury-prone. Digit helps companies keep their production levels and their output up in areas where humans generally do not want those jobs.

     

    MARIA: So, these are filling a need where it is a dirty job. But there is also this fear that robots are taking over our jobs, and that companies across the world are racing to put robots in place in the workforce and firing humans. Digit has already clocked more than 65,000 hours of operation across nine states. That is pretty incredible.

     

    PEGGY JOHNSON: These are jobs that are unfilled. Humans generally do not want them. We have a retiring workforce in manufacturing, younger generations do not want these jobs, and we also have reshoring going on. That has created a gap of about a million jobs in the U.S., and it was only about half a million a few years ago. The number is growing.

     

    MARIA: That is a rising number, and it certainly is enabling companies to do more. We’re looking at a shot of one robot right now. Tell us what these robots look like in a practical way. Is it just a machine next to you, or are they increasingly trying to take on humanoid looks?

     

    PEGGY JOHNSON: We say we are human-centric. We did not set out to build a facsimile of a human at all. We said, what is the job that needs to be done, and what type of device can fill that best? For instance, we do not have five-finger hands. We have grippers, because those are the right tool for lifting heavy things over and over again.

     

    MARIA: These robots are designed to take on repetitive and physically demanding tasks in places like warehouses and manufacturing facilities. But of course, the concern is that the rise of robots will displace human workers. During our special AI Week, we had Betsy Atkins, who sits on the boards of many companies, saying that sometimes these agentic AI assistants can behave unpredictably, and safety is a big part of this.

     

     

     

     

    PEGGY JOHNSON: Right now, all humanoids have to operate inside of a work cell at these facilities, cordoned off from humans, just like any other big, heavy automation. By the end of this year, though, Agility will have solved for bringing robots outside of the work cell so they can walk through these facilities in a safe manner while keeping humans safe as they come in close proximity.

     

    MARIA: So, what does being safe mean specifically with the robot?

     

    PEGGY JOHNSON: They are large automated devices with arms and limbs that are powerful enough to lift 50 pounds over and over again, all day long, for three shifts. So that type of device needs to be kept safe from humans. We will be able to walk in close proximity to humans by the end of this year through cooperative safety.

     

    MARIA: What industries beyond warehouses and manufacturing do you believe will adopt robots first? Are there areas you think are more ripe than others?

     

    PEGGY JOHNSON: Any industry that is moving heavy material through its facilities. One that is really rising up is the automotive industry. They have a lot of this type of work, and they can’t find workers to step in and do it. It is generally part of someone’s job that they like the least. So we see the automotive industry as very interested.

     

    MARIA: Everybody is talking about AI. We’re doing AI every single day. What is AI enabling in these robots today that was not possible a year ago?

     

    PEGGY JOHNSON: Generally, robots need to learn their tasks, and AI has supercharged that. We used to have an engineer write a program that directed where the robot would go. Now AI can help us teach the robot new skills very, very quickly and improve coordination and that sort of thing.

     

    MARIA: How heavy is the robot? Are we talking about 100 pounds, 150 pounds?

     

    PEGGY JOHNSON: Our robot is about 200 pounds.

     

    MARIA: Two hundred pounds. So that speaks to the safety issue. You are operating with a 200-pound machine next to you, with arms and legs doing all sorts of things.

     

    PEGGY JOHNSON: Correct. That is why you have to be very careful.

     

    MARIA: I’m glad you brought up the safety issue, because that is critical. Anthropic CEO Dario Amodei published a memo warning that AI will drive labor market disruption, saying it could be longer and bigger than people expect, and certainly lasting longer than previous technological shifts. Peggy, what is your reaction to that? What are you expecting in terms of change in the workforce as a result of all of this?

     

    PEGGY JOHNSON: We see robots as a tool to augment humans and give them more time to do higher-value work rather than this very manual work. It is also going to open up a number of new jobs. Robots need to be monitored. They need to be maintained. They need to be manufactured. All of that will require humans.

     

    MARIA: This is really the industrial side of this, right? But the idea that all of us will want our own assistant, our own robot, is out there right now. What is the cost of these robots? If you wanted to buy your own assistant that is a machine with you doing these repetitive tasks, how much would that cost?

     

    2

     

     

     

    PEGGY JOHNSON: We offer robots-as-a-service, so it is a monthly fee. We offer it at a discount to fully burdened human labor, so companies that adopt can see ROI from day one if they could have found a human to take the role, and that has been the challenge.

     

    MARIA: So you are paying monthly. It is a service. You’re not buying it outright. The other day on the show, someone said you’ll be able to buy a robot for $40,000, and you can buy a car for $50,000. Do you agree with that?

     

    PEGGY JOHNSON: Over time, definitely.

     

    MARIA: The other question is around the future of manufacturing. The administration wants defense, pharmaceuticals and other supply chains brought back. Can that only be done efficiently with robotics?

     

    PEGGY JOHNSON: I believe so, because already there is an existential problem with the lack of humans to fill the roles in manufacturing. As we onshore, that burden will only get higher. That will grow, and we will need further automation, including robots.

     

    MARIA: What are you expecting in terms of reception from companies? Tell us about the booked orders that you mentioned earlier. Who is buying?

     

    PEGGY JOHNSON: These are industrial companies that have labor gaps, and they see this as a way to prevent their output and production from being impacted. They want to ensure they can continue to produce at the levels they are at right now, and they see a gap where they are not able to find these workers.

     

    MARIA: This is a new world, Peggy. How did you get involved in this?

     

    PEGGY JOHNSON: I have always loved hardware, and to me this seems very much like the start of quite a disruptive new era for humans, but a good one. It will be helping them out.

     

    MARIA: They’re calling it a re-industrial revolution, what we’re seeing underway. What a moment in time, Peggy. Thank you.

     

    PEGGY JOHNSON: Thanks, Maria.

     

    MARIA: Great moment to be alive, that’s for sure. Peggy Johnson, we will be watching Agility.

     

    ***

     

    3

     

     

    Additional Information About the Proposed Transaction and Where to Find It

     

    The proposed transaction will be submitted to shareholders of Churchill for their consideration. Churchill intends to file a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”), which will include preliminary and definitive proxy statements to be distributed to Churchill’s shareholders in connection with Churchill’s solicitation of proxies for the vote by Churchill’s shareholders in connection with the proposed transaction and other matters to be described in the Registration Statement, as well as the prospectus relating to the offer of the securities to be issued to Agility stockholders in connection with the completion of the proposed transaction. After the Registration Statement has been filed and declared effective, a definitive proxy statement/prospectus/consent solicitation statement and other relevant documents will be mailed to Agility stockholders and Churchill shareholders as of the record date established for voting on the proposed transaction. Before making any voting or investment decision, Churchill and Agility shareholders and other interested persons are advised to read, once available, the preliminary proxy statement/prospectus and any amendments thereto and, once available, the definitive proxy statement/prospectus, as well as other documents filed with the SEC by Churchill in connection with the proposed transaction, as these documents will contain important information about Churchill, Agility and the proposed transaction. Shareholders may obtain a copy of the preliminary or definitive proxy statement/prospectus, once available, as well as other documents filed by Churchill with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a written request to Churchill Capital Corp XI, 640 Fifth Avenue, 14th Floor, New York, NY 10019.

     

    Forward-Looking Statements

     

    This communication includes “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. We have based these forward-looking statements on current expectations and projections about future events.

    These statements include: statements relating to, without limitation: our ability to consummate the Merger and PIPE Investment and the satisfaction or waiver of the closing conditions set forth in the Merger Agreement and Subscription Agreement; the occurrence of any other event, change or other circumstances that could give rise to the termination of the Merger Agreement or Subscription Agreements; projections of market opportunity and market share; estimates of customer adoption rates and usage patterns; projections regarding Agility’s future development plans; the timing and success of Agility’s future development plans; the ability of Agility to implement its strategic initiatives and continue to innovate its existing products and services; the potential for share price appreciation; the expected timing of announcement and close of the potential transaction; Agility’s economic opportunity and total addressable market; the expected amount of gross transaction proceeds and the planned pre-money valuation of Agility; expectations regarding Agility’s ability to attract, retain and expand its customer base; Agility’s deployment of proceeds from capital raising transactions; Agility’s expectations concerning relationships with strategic partners, suppliers, regulatory bodies and other third parties; Agility’s ability to maintain, protect and enhance its intellectual property; future ventures or investments in companies, products, services or technologies; development of favorable regulations affecting Agility’s markets; the potential benefits of the proposed transaction and expectations related to its terms and timing; and the potential for the combined company to increase in value.

     

    These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions, many of which are beyond the control of Agility and Churchill.

     

    4

     

     

    These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause Churchill’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such statements. Such risks and uncertainties include: that Agility is pursuing an emerging technology, faces significant technical challenges and may not achieve commercialization or market acceptance; Agility’s historical net losses and limited operating history; Agility’s expectations regarding future financial performance, capital requirements and unit economics; Agility’s use and reporting of business and operational metrics; Agility’s competitive landscape; Agility’s dependence on members of its senior management and its ability to attract and retain qualified personnel; the potential need for additional future financing; Agility’s ability to manage growth and expand its operations; potential future acquisitions or investments in companies, products, services or technologies; Agility’s reliance on strategic partners and other third parties; Agility’s ability to maintain, protect and defend its intellectual property rights; risks associated with privacy, data protection or cybersecurity incidents and related regulations; the use, rate of adoption and regulation of artificial intelligence and machine learning; uncertainty or changes with respect to laws and regulations; uncertainty or changes with respect to taxes, trade conditions and the macroeconomic environment; the combined company’s ability to maintain internal control over financial reporting and operate a public company; the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect the price of Churchill’s securities; the failure by the parties to satisfy the conditions to consummation of the proposed transaction, including the approval of Churchill’s shareholders; the possibility that required regulatory approvals for the proposed transaction are delayed or are not obtained, which could adversely affect the combined company or the expected benefits of the proposed transaction; the risk that shareholders of Churchill could elect to have their shares redeemed, leaving the combined company with insufficient cash to execute its business plans; the level of redemptions of Churchill’s public shareholders; the ability of Agility to grow and manage growth, maintain relationships with customers and retain its management and key employees; costs related to the proposed transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; the outcome of any legal proceedings or government investigations that may be commenced against Agility or Churchill; failure to realize the anticipated benefits of the proposed transaction; Agility’s estimates of expenses and profitability; the evolution of the markets in which Agility competes; the ability of Churchill or the combined company to issue equity or equity-linked securities in connection with the proposed transaction or in the future; and other factors described in Churchill’s filings with the SEC. Additional information concerning these and other factors that may impact such forward-looking statements can be found in filings and potential filings by Agility, Churchill or the combined company resulting from the proposed transaction with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, these statements reflect the expectations, plans and forecasts of Agility’s and Churchill’s management as of the date of this communication; subsequent events and developments may cause their assessments to change. While Agility and Churchill may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. Accordingly, undue reliance should not be placed upon these statements.

     

    In addition, statements that “we believe” and similar statements reflect Churchill’s beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this communication, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and Churchill’s statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

     

    5

     

     

    An investment in Churchill is not an investment in any of Churchill’s founders’ or sponsors’ past investments, companies or affiliated funds.

     

    The historical results of those investments are not indicative of future performance of Churchill, which may differ materially from the performance of Churchill’s founders’ or sponsors’ past investments.

     

    Participants in the Solicitation

     

    Churchill, Agility and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from Churchill’s shareholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of Churchill’s shareholders in connection with the proposed transaction will be set forth in proxy statement/prospectus statement when it is filed by Churchill with the SEC. You can find more information about Churchill’s directors and executive officers in Churchill’s final prospectus related to its initial public offering filed with the SEC on December 16, 2025. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus statement when it becomes available. Shareholders, potential investors and other interested persons should read the proxy statement/prospectus statement carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources described above.

     

    No Offer or Solicitation

     

    This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This communication is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the securities described herein in the United States or any other jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or exemptions therefrom. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

     

    6

    Get the next $CCXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCXI

    DatePrice TargetRatingAnalyst
    8/4/2022$81.00Buy
    Canaccord Genuity
    11/10/2021$107.00 → $110.00Strong Buy
    Raymond James
    10/11/2021$14.00 → $38.00Underweight → Neutral
    JP Morgan
    10/11/2021$64.00Mkt Perform → Outperform
    SVB Leerink
    10/11/2021$62.00 → $107.00Outperform → Strong Buy
    Raymond James
    10/8/2021$62.00 → $107.00Outperform → Strong Buy
    Raymond James
    10/8/2021Neutral → Overweight
    Piper Sandler
    7/7/2021$26.00 → $31.00Hold → Buy
    Stifel
    More analyst ratings

    $CCXI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TAVNEOS issued to CHEMOCENTRYX, INC.

    Submission status for CHEMOCENTRYX, INC.'s drug TAVNEOS (ORIG-1) with active ingredient AVACOPAN has changed to 'Approval' on 10/07/2021. Application Category: NDA, Application Number: 214487, Application Classification: Type 1 - New Molecular Entity

    10/15/21 3:42:50 PM ET
    $CCXI

    $CCXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agility Robotics Strengthens Executive Leadership Team with Appointment of Michael Beer as Chief Financial Officer

    Experienced public company finance executive joins Agility as company expands commercial momentum and prepares to become the first publicly listed U.S. pure-play humanoid robotics company.SALEM, Ore., July 23, 2026 /PRNewswire/ -- Agility Robotics, a leading humanoid robotics and Physical AI company, today announced the appointment of Michael Beer as Chief Financial Officer as the company continues to strengthen its executive leadership team ahead of its planned public listing through its previously announced business combination with Churchill Capital Corp XI (NASDAQ:CCXI). As part of this planned evolution of the leadership t

    7/23/26 8:00:00 AM ET
    $CCXI
    $NRGV
    Industrial Machinery/Components
    Miscellaneous

    Agility Opens New Fremont Facility to Accelerate Physical AI Development

    Bay Area facility will advance the AI technologies that enable its humanoid robot, Digit, to learn new skills, supporting expanded capabilities across commercial deployments.FREMONT, Calif., July 16, 2026 /PRNewswire/ -- Agility, a leading humanoid robotics and Physical AI company, today announced the opening of its new Fremont, California, facility designed to accelerate Physical AI developments that directly improve performance in customer operations. The new site will serve as the company's software and capabilities hub, where engineering teams will train, test and advance the AI technologies that enable Agility's humanoid, Digit, to learn new skills and perform more sophisticated tasks i

    7/16/26 3:00:00 PM ET
    $CCXI

    Agility Robotics and Churchill Capital Corp XI Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination

    Transaction Expected to Create The Only Publicly Listed Pure-Play Humanoid Company with Proven, Active Commercial Deployments Agility Robotics, Inc. ("Agility" or the "Company") creator of the general-purpose humanoid robot Digit, and Churchill Capital Corp XI (NASDAQ:CCXI) ("CCXI" or "Churchill XI"), a special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC"). The submission of the Registration Statement marks an important milestone toward the completion of the previously disclosed proposed business combination between Agility and

    7/14/26 11:30:00 AM ET
    $CCXI

    $CCXI
    SEC Filings

    View All

    SEC Form 425 filed by Churchill Capital Corp XI

    425 - Churchill Capital Corp XI (0002074973) (Subject)

    7/16/26 5:12:22 PM ET
    $CCXI

    SEC Form 425 filed by Churchill Capital Corp XI

    425 - Churchill Capital Corp XI (0002074973) (Subject)

    7/14/26 4:34:29 PM ET
    $CCXI

    SEC Form 8-K filed by Churchill Capital Corp XI

    8-K - Churchill Capital Corp XI (0002074973) (Filer)

    7/14/26 4:30:42 PM ET
    $CCXI

    $CCXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity resumed coverage on ChemoCentryx with a new price target

    Canaccord Genuity resumed coverage of ChemoCentryx with a rating of Buy and set a new price target of $81.00

    8/4/22 8:51:51 AM ET
    $CCXI

    Raymond James reiterated coverage on ChemoCentryx with a new price target

    Raymond James reiterated coverage of ChemoCentryx with a rating of Strong Buy and set a new price target of $110.00 from $107.00 previously

    11/10/21 9:06:49 AM ET
    $CCXI

    ChemoCentryx upgraded by JP Morgan with a new price target

    JP Morgan upgraded ChemoCentryx from Underweight to Neutral and set a new price target of $38.00 from $14.00 previously

    10/11/21 8:32:48 AM ET
    $CCXI

    $CCXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lapping Paul

    3 - Churchill Capital Corp XI (0002074973) (Issuer)

    3/19/26 8:44:45 PM ET
    $CCXI

    SEC Form 3 filed by new insider Murphy Stephen Anthony

    3 - Churchill Capital Corp XI (0002074973) (Issuer)

    3/19/26 8:43:25 PM ET
    $CCXI

    Officer Klein Michael Stuart bought $5,000,000 worth of Class A Ordinary Shares (500,000 units at $10.00) (SEC Form 4)

    4 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/19/25 5:16:36 PM ET
    $CCXI

    $CCXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Klein Michael Stuart bought $5,000,000 worth of Class A Ordinary Shares (500,000 units at $10.00) (SEC Form 4)

    4 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/19/25 5:16:36 PM ET
    $CCXI

    $CCXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    9/12/22 11:13:14 AM ET
    $CCXI

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    2/9/22 3:33:37 PM ET
    $CCXI

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    2/9/22 9:11:44 AM ET
    $CCXI

    $CCXI
    Leadership Updates

    Live Leadership Updates

    View All

    ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

    SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine. "With more than 25 years developing and refining her therapeutics commercial expertise, Jennifer is uniquely positioned to add immediate value to our TAVNEOS® (avacopan) commercial efforts," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Jennifer's values closely align with our organization, and we are confident this addition

    7/5/22 8:30:00 AM ET
    $CCXI

    ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer

    Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors (where she has served since March of 2019) as an executive employee director. Dr. Jain, a board-certified rheumatologist, brings more than 20 years of drug de

    10/11/21 8:30:00 AM ET
    $CCXI

    ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors

    MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021. “Susan Kanaya’s many fundamental contributions have been key to ChemoCentryx’s growth and prosperity,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Over many formative years of our enterprise, she ensured our strong financial position, allowing us to achieve our operational plans and thus increasing shareholder value while serving patients’ needs. As a

    3/8/21 8:30:00 AM ET
    $CCXI

    $CCXI
    Financials

    Live finance-specific insights

    View All

    AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

    TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. "ChemoCentryx enhances Amgen's leading inflammation and nephrology portfolio and includes TAVNEOS® (avacopan), a first-in-cl

    10/20/22 9:05:00 AM ET
    $AMGN
    $CCXI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

    SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, on August 8, 2022. About ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. 

    8/9/22 8:30:00 AM ET
    $CCXI

    ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

    SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307-1963 (International). The conference ID number is 9726781. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast wil

    8/2/22 4:05:00 PM ET
    $CCXI